

PRISM II

A Study to Assess the Safety, Tolerability and Effectiveness of NUEDEXTA® (Dextromethorphan 20mg/Quinidine 10mg) in the Treatment of Pseudobulbar Affect (PBA)

Thank you for participating in the PRISM II Study! This study will provide valuable information regarding the treatment of Pseudobulbar affect (PBA). We are working hard to make this a valuable experience for you, the investigator, as well as your patients who may be eligible for this study. As we move forward, we will continue to provide you updates on the progress of the trial as well as provide key information to assist you in your participation --- Charles Yonan, PRISM II Study Director, Avanir.

Congratulations to the following sites that are the leading enrollers:

- Dr. Antin – Decatur, GA
- Dr. Axley – Pensacola, FL
- Dr. Chappel - Kissimmee, FL
- Dr. Fullerton – San Francisco, CA
- Dr. Pardo – Baytown, TX

What other resources could be used to find potential patients

- Practice databases
- Colleague awareness and referrals
- Local access to patient groups

Looking for Patients to Enroll into PRISM II?

A quick screen can be used to provide the PBA brochure with the CNS-LS to any of your patients with

- Dementia
- Stroke
- TBI

What if I have questions or need assistance?

- All questions regarding Contracting, Regulatory documents, Training or patient enrollment should be directed to Optum (contact information below)
- All question for IRB issues or IRB training requirements should be directed to Copernicus IRB (contact information below)

KEY CONTACT INFORMATION

**Optum-PRISM II
Helpline**
888-899-4502

**Optum-PRISM II
Fax**
888-277-3505

**Optum-PRISM II
Email**
prism2@optum.com


IRB Website
www.cgirb.com

NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) 20mg/10mg capsules can interact with other medications and cause serious side effects. NUEDEXTA is contraindicated in patients taking certain drugs and in patients with specific cardiovascular risk factors. These are not all the risks from use of NUEDEXTA. Please see the [Important Safety Information](#) and full [Prescribing Information](#)

Current Study Metrics- April, 2013


❖ Activated sites - 23

Investigator Specialty



■ Neurology ■ Psychiatry ■ Geriatric Med

Patient Type



■ Dementia ■ TBI ■ Stroke

OVERVIEW OF THE PRISM II PROCESS FOR SITES TO GET ACTIVATED!



Additional Resources:

Information regarding Avanir Pharmaceuticals - www.Avanir.com

Information regarding Pseudobulbar affect (PBA) - www.PBAfacts.com

Information regarding NUEDEXTA® - www.NUEDEXTA.com

NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) 20mg/10mg capsules can interact with other medications and cause serious side effects. NUEDEXTA is contraindicated in patients taking certain drugs and in patients with specific cardiovascular risk factors. These are not all the risks from use of NUEDEXTA. Please see the [Important Safety Information](#) and full [Prescribing Information](#)